ClinicalTrials.gg
CompletedNCT05439629Updated Dec 8, 2025

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

A Phase 3 interventional study of BAT5906 injection and Lucentis in Neovascular (Wet) Age-related Macular Degeneration, sponsored by Bio-Thera Solutions. Completed at 48 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Bio-Thera Solutions · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
5th of 91
488 · median 62
Started
2022
with 6 others
Phase 3
18 of 106
4 open now
Registered
56th of 106
by date
Lead sponsor
3 of 106
Bio-Thera Solutions

Among the 106 studies in Macular Degeneration with a site in China, this one is the 5th largest by enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2022, is one of 18 in phase 3, and was the 56th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and whether the eyes had received anti-VEGF drug treatment. The experimental group received BAT5906 injection. The control group received Lucentis® treatment. Only 1 eye per subject was included in this study.

Read the detailed description

A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and whether the eyes had received anti-VEGF drug treatment. The experimental group received BAT5906 injection. The control group received Lucentis® treatment. Only 1 eye per subject was included in this study.

The administration regimen was as follows: once every 4 weeks, 4mg BAT5906 or 0.5mg Lucentis® were injected intravitreal each time, the treatment period of the study was 48 weeks, a total of 13 administration times, the last follow-up was conducted at the 52nd week, the last visit did not require treatment, only efficacy and safety assessment, and blood samples were collected as required.

Ophthalmic examination, vital signs, physical examination, and laboratory examination were performed for efficacy and safety assessment according to the test procedures specified in the protocol, and blood samples were collected for immunogenicity indicators. Change in best corrected visual acuity (BCVA) from baseline was assessed by ETDRS visual acuity chart at 4-week intervals. The primary efficacy measure was the change in BCVA from baseline at 52 weeks. Secondary efficacy measures were the change in best corrected visual acuity (BCVA) of the target eye from baseline and the change in macular fovea thickness (CRT) from baseline at weeks 12, 24, 36 and 48.

Blood samples were collected according to the time points specified in the program, and the serum anti-drug antibody (ADA) was detected. Titer analysis and neutralizing antibody (Nab) analysis were performed on the samples confirmed as positive by ADA.

A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and whether the eyes had received anti-VEGF drug treatment. The experimental group received BAT5906 injection. The control group received Lucentis® treatment. Only 1 eye per subject was included in this study.

The administration regimen was as follows: once every 4 weeks, 4mg BAT5906 or 0.5mg Lucentis® were injected intravitreal each time, the treatment period of the study was 48 weeks, a total of 13 administration times, the last follow-up was conducted at the 52nd week, the last visit did not require treatment, only efficacy and safety assessment, and blood samples were collected as required.

Ophthalmic examination, vital signs, physical examination, and laboratory examination were performed for efficacy and safety assessment according to the test procedures specified in the protocol, and blood samples were collected for immunogenicity indicators. Change in best corrected visual acuity (BCVA) from baseline was assessed by ETDRS visual acuity chart at 4-week intervals. The primary efficacy measure was the change in BCVA from baseline at 52 weeks. Secondary efficacy measures were the change in best corrected visual acuity (BCVA) of the target eye from baseline and the change in macular fovea thickness (CRT) from baseline at weeks 12, 24, 36 and 48.

Blood samples were collected according to the time points specified in the program, and the serum anti-drug antibody (ADA) was detected. Titer analysis and neutralizing antibody (Nab) analysis were performed on the samples confirmed as positive by ADA.

03

Conditions studied

  • Neovascular (Wet) Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and sign the , and be willing to follow up according to the time specified in the trial;
  2. Age 50-85 years old (including boundary value), male and female;
  3. Study the subjects who were diagnosed with neovascular age-related macular degeneration and still had active lesions confirmed by imaging examination. Active lesions were defined as the presence of any of the following lesions in the macular area: ① intraretinal fluid; ② Lipid exudation in the retina; ③ Subretinal fluid; (4) Subretinal hemorrhage; (5) Retinal pigment epithelium detachment; ⑥ Choroidal neovascularization leakage;
  4. The total area of the study eye lesions ≤30mm2(12 optic disc areas) was confirmed by the film reading center before randomization;
  5. The BCVA of the study eye at screening and baseline was 73-19 letters (ETDRS visual acuity chart, including boundary values), equivalent to Snellen visual acuity 20/40 to 20/400;
  6. BCVA≥19 letters, equivalent to Snellen visual acuity ≥20/400, measured by ETDRS visual chart at screening and baseline in non-study eyes.

Exclusion criteria

Exclusion Criteria:

  1. The study eyes received any intravitreal anti-VEGF therapy (such as bevacizumab, abbercept, ranibizumab, conbercept, etc.) within 3 months before randomization;
  2. The study eyes had received the following treatments within 3 months before randomization: verteporfin photodynamic therapy (PDT), macular laser photocoagulation, transpillary thermotherapy (TTT), and other surgeries for AMD;
  3. The study eyes had undergone the following ophthalmic surgeries: vitrectomy, anti-glaucoma surgery, and macular transposition. The study eyes had undergone internal eye surgery (including cataract surgery) within 3 months before randomization, or external eye surgery within 1 month before randomization;
  4. The study eyes received intravitreal injection treatment (such as triamcinolone acetonide and dexamethasone) within 3 months before randomization, intravitreal injection of dexamethasone sustained release within 6 months, and injection of long-acting (such as triamcinolone acetonide, etc.) within, periocular or subconjunctival injection of any eye 3 months before randomization;
  5. Study eyes with ocular diseases affecting central vision (such as diabetic retinopathy, retinal vein occlusion, uveitis, vascular striation, pathological myopia, retinal detachment, macular hole, macular epiretinal membrane, toxoplasmosis, optic nerve diseases);
  6. Study eyes with foveal ground pattern atrophy, scar or fibrosis, dense subfoveal hard exudation, retinal pigment epithelium (RPE) tear involving the center of the macula (confirmed by the reading center during screening);
  7. The study eyes had choroidal neovascularization not caused by nAMD, progressive retinopathy affecting corrected visual acuity, and any eye had vitreous hemorrhage or a history of vitreous hemorrhage, or a history of retinal detachment;
  8. The equivalent spherical mirror of the study eye with refractive error showed more than -6.0 diopters. For patients with previous refractive surgery or cataract surgery, the preoperative refractive error of the study eye should not exceed -6.0 diopters;
  9. The study eyes were lens free (excluding IOL eyes) or posterior lens capsule rupture (except YAG laser posterior capsuleotomy after IOL implantation more than 1 month before screening);
  10. The study eye has obvious refractive interstitial opacity or pupil failure, including cataract and corneal opacity, which may interfere with visual acuity assessment, safety assessment or fundus photography;
  11. The study eyes had pupil afferent defect (APD);
  12. Study eyes had uncontrolled glaucoma at randomization, defined as intraocular pressure that remained higher than 25mmHg after medical treatment or as judged by the investigator;
  13. Non-study eyes received photodynamic therapy (PDT) within 1 month before randomization;
  14. History of idiopathic or associated uveitis in any eye;
  15. Pseudocyst stripping syndrome in any eye;
  16. Active eye infection in any eye (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, iridecocyclitis, endophthalmitis);
  17. Systemic drugs that cause crystal or retinal toxicity, such as deferoxamine, chloroquine/hydroxychloroquine, phenothiazine and ethambutol or tamoxifen, are currently being used or may be required;
  18. Allergic reaction or history to sodium fluorescein and indocyanine green, allergic history to protein products for therapeutic or diagnostic use, or known allergic reaction to any monoclonal antibody;
  19. Patients who had surgery within 1 month before randomization and the surgery did not heal, and the investigator judged that the study drug had an effect on healing;
  20. Presence of active systemic infectious disease under treatment;
  21. History of myocardial infarction, unstable angina, coronary revascularization, cerebrovascular accident (including ), other thromboembolic diseases (such as thromboembolic angiitis, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, etc.), (NYHA) grade ≥II cardiac dysfunction within 6 months before randomization, Severe unstable ventricular arrhythmias;
  22. Patients with active disseminated intravascular coagulation and significant bleeding tendency (such as hemoptysis, hematemesis, severe purpura, etc.) within 3 months before randomization, or who had received anticoagulant and antiplatelet therapy other than aspirin /NSAIDs within 14 days before screening;
  23. Poorly controlled hypertension before randomization (defined as sitting systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after antihypertensive medication);
  24. Any uncontrollable clinical problems (such as serious mental, neurological, cardiovascular, respiratory and other system diseases and malignant tumors);
  25. Abnormal liver and kidney function ( and AST should not be higher than 2.5 times of the value in the central laboratory; Crea and BUN shall not be higher than 2 times of the upper limit of normal value in the central laboratory);
  26. Abnormal coagulation function ( > upper limit of normal 3 seconds or activated partial thromboplastin time > upper limit of normal 10 seconds);
  27. Patients with any of the following infections: active (HBV DNA > 1000 IU/mL if HBsAg(+)), , AIDS, or syphilis (syphilis RPR confirmatory test positive);
  28. Planned parenthood during pregnancy or lactation, or during the study period and within 6 months after the study. The pregnancy test of fertile female patients was positive during the screening period;
  29. Subjects who have participated in any drug (excluding vitamins and minerals) in the clinical trial within 3 months before randomization and have been treated with the experimental drug or device;
  30. The researcher believes that it is not suitable for this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Experimental group:BAT5906

    Intravitreal injection; Dosage: 4.0 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.

    Drug: BAT5906 injection

  • Active comparator
    Control group:Lucentis®

    Intravitreal injection; Dosage: 0.5 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.

    Drug: Lucentis

Interventions

  • 4.0 mg/eye/time, 50 μl, intravitreal injection

  • 0.5 mg/eye/time, 50 μl, intravitreal injection

06

What researchers measure

Primary outcomes

  1. The change in the BCVA value

    Compared to baseline, two groups of subjects studied the value of changes in ocular 52nd week BCVA

    Time frame: Week 52

  2. The change in the BCVA value

    Compared to baseline, two groups of subjects studied the changes in bcVA at weeks 12, 24, 36, and 48 of the eye

    Time frame: at weeks 12, 24, 36, and 48

  3. BCVA increased the proportion of subjects with >10, >15, ≥30 words

    Compared with baseline, the proportion of subjects with 30 words of BCVA in the 24th and 52nd weeks of the study eye was improved \> 10, \>15, ≥ 30 words;

    Time frame: in the 24th and 52nd weeks

  4. BCVA reduced the proportion of subjects < 10, < 15 words

    Compared with baseline, the proportion of subjects in both groups who studied eye bcVA at weeks 24 and 52 decreased \<10, \< 15 words

    Time frame: at weeks 24 and 52

  5. Changes in the thickness of the macular fovea (CRT).

    Changes in the thickness of the macular fovea (CRT) at weeks 12, 24, 36, 48, and 52 were studied in both groups of subjects compared to baseline

    Time frame: at weeks 12, 24, 36, 48, and 52

Secondary outcomes

  1. Vital signs

    Number of participants with abnormal vital signs

    Time frame: Weeks 1 to 52

  2. physical examination

    Number of participants with abnormal physical examination findings

    Time frame: Weeks 1 to 52

  3. Laboratory tests

    Number of participants with abnormal laboratory test results

    Time frame: Weeks 1 to 52

  4. electrocardiogram( ECG )

    Number of participants with abnormal ECG readings

    Time frame: Weeks 1 to 52

  5. Antibiotic antibodies (ADA)

    Resistance antibody (ADA) situation in the subject

    Time frame: Weeks 1 to 52

  6. Adverse events(AE)

    Ocular and non-ocular adverse events (AE) and serious adverse events (SAE)

    Time frame: Weeks 1 to 52

  7. Adverse events of particular concern (possible adverse reactions to the eye)

    Endophthalmia, increased intraocular pressure, subconjunctival hemorrhage, ocular foreign body sensation, visual impairment, corneal abrasions, lens damage, retinal detachment, retinal artery occlusion, etc.; Possible systemic adverse effects include non-ocular bleeding, increased blood pressure, and thromboembolic events

    Time frame: Weeks 1 to 52

Other outcomes

  1. Immunogenicity evaluation

    Blood samples from BAT5906 and Lucentis® injections were detected for ADA detection and analysis to detect anti-BAT5906 antibodies (ADA). Serum antibodies (ADA) are tested, and neutralizing antibody (Nab) analysis will continue if the ADA is confirmed positive.

    Time frame: Weeks 1 to 52

07

Study locations

48 sites
  • Affiliated Hospital of Inner Mongolia Medical University
    Beijing, China
  • Beijing Chao Yang Hospital
    Beijing, China
  • Beijing Hospital
    Beijing, China
  • China-Japan Friendship Hospital
    Beijing, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • Xiangya Hospital of Central South University
    Changsha, China
  • The First Affiliated Hospital of Army Medical University (Southwest Hospital)
    Chongqing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • First Affiliated Hospital of Fujian Medical University
    Fujian, China
  • First Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, China
  • Guangzhou Aier Eye Hospital
    Guangzhou, China
  • Sun Yat-sen Ophthalmic Center, Sun Yat-sen University
    Guangzhou, China
  • The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
    Guangzhou, China
  • Affiliated Hospital of Guizhou Medical University
    Guiyang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • The Second Hospital of Anhui Medical University
    Hefei, China
  • People's Hospital of Wuhan University (Hubei Provincial People's Hospital)
    Hubei, China
  • The First Hospital of Jilin University
    Jilin City, China
  • Jinan Second People's Hospital
    Jinan, China
  • The Affiliated Eye Hospital of Shandong University of Chinese Medicine
    Jinan, China
  • Jinzhong First People's Hospital
    Jinzhong, China
  • The First People's Hospital of Kunming
    Kunming, China
  • Luoyang Third People's Hospital
    Luoyang, China
  • The Affiliated Eye Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Provincial Hospital of Traditional Chinese Medicine
    Nanjing, China
  • Affiliated Hospital of Nantong University
    Nantong, China
  • Ningbo Eye Hospital
    Ningbo, China
  • Pingxiang People's Hospital
    Pingxiang, China
  • People's Hospital of Quzhou
    Quzhou, China
  • Huashan Hospital
    Shanghai, China
  • Shanghai Oriental Hospital
    Shanghai, China
  • Shanghai University of Traditional Chinese Medicine
    Shanghai, China
  • The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Shantou University-Chinese University of Hong Kong Joint Shantou International Eye Centre
    Shantou, China
  • The Fourth People's Hospital of Shenyang
    Shenyang, China
  • Shenzhen People's Hospital
    Shenzhen, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, China
  • Weifang Eye Hospital
    Weifang, China
  • Wenzhou Medical University Affiliated Optometry Hospital
    Wenzhou, China
  • Hebei Provincial Eye Hospital
    Xingtai, China
  • Xuzhou Central Hospital
    Xuzhou, China
  • Yantai Yuhuangding Hospital
    Yantai, China
  • Henan Eye Center (Henan Eye Hospital)
    Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
  • The Second People's Hospital of Zhengzhou
    Zhengzhou, China
  • Zunyi Medical College
    Zunyi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2025, 33 months.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 33 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 30, 2022
StartActual
Jul 7, 2022
Primary completionActual
Apr 22, 2025
CompletionActual
Apr 22, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05439629
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Jul 7, 2022
Primary completion
Apr 22, 2025
Completion
Apr 22, 2025
Last update
Dec 8, 2025

Study contacts

Youxin Chen, Doctor
principal investigator · Peking Union Medical College
Xiaolin Liu, Doctor
principal investigator · Affiliated Optometry Hospital of Wenzhou Medical University
Mingwei Zhao, Doctor
principal investigator · Peking University People's Hospital
Yi Chen, Doctor
principal investigator · China-Japan Friendship Hospital
Hong Dai, Doctor
principal investigator · Beijing Hospital
Yong Tao, Doctor
principal investigator · Beijing Chao Yang Hospital
Linna Lu, Doctor
principal investigator · The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Hongping Cui, Doctor
principal investigator · Shanghai Oriental Hospital
Xiaolin Liang, Doctor
principal investigator · Sun Yat-sen Ophthalmic Center, Sun Yat-sen University
Pengxia Wan, Doctor
principal investigator · First Affiliated Hospital, Sun Yat-Sen University
Yuqing Lan, Doctor
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Haoyu Chen, Doctor
principal investigator · Shantou University-Chinese University of Hong Kong Joint Shantou International Eye Centre
Xiyuan Zhou, Doctor
principal investigator · The Second Affiliated Hospital of Chongqing Medical University
Xiaohong Meng, Doctor
principal investigator · The First Affiliated Hospital of Army Medical University (Southwest Hospital)
Jinglin Yi, Doctor
principal investigator · The Affiliated Eye Hospital of Nanchang University
Hongmei Zheng, Doctor
principal investigator · People's Hospital of Wuhan University (Hubei Provincial People's Hospital)
Liuhua Tong, Doctor
principal investigator · People's Hospital of Quzhou
Zongming Song, Doctor
principal investigator · Henan Eye Center (Henan Eye Hospital)
Shenzhi Liang, Doctor
principal investigator · The First Affiliated Hospital of Zhengzhou University
Junfeng Mao, Doctor
principal investigator · Xiangya Hospital of Central South University
Xiangwen Shu, Master
principal investigator · Jinan Second People's Hospital
Yuanbin Li, Doctor
principal investigator · Yantai Yuhuangding Hospital
Shanjun Cai, Doctor
principal investigator · Zunyi Medical College
Xian Wang, Doctor
principal investigator · The Affiliated Hospital Of Guizhou Medical University
Xu Li, Master
principal investigator · Fourth People's Hospital of Shenyang
Rongrong Zhu, Bachelor
principal investigator · Affiliated Hospital of Nantong University
Wei Wei, Doctor
principal investigator · Jiangsu Province Hospital of Traditional Chinese Medicine
Yabin Sun, Doctor
principal investigator · The First Hospital of Jilin University
Liming Tao, Doctor
principal investigator · The Second Hospital of Anhui Medical University
Hongjian Ma, Doctor
principal investigator · Aier Eye Hospital, Guangzhou
Yaohong Wu, Doctor
principal investigator · Second Hospital of Shanxi Medical University
Jian Guo, Doctor
principal investigator · First Affiliated Hospital of Fujian Medical University
Xiaoling Luo, Doctor
principal investigator · Shenzhen People's Hospital
Qiuhong Liu, Doctor
principal investigator · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Xinquan Liu, Doctor
principal investigator · Shanghai University of Traditional Chinese Medicine
Lifei Wang, Doctor
principal investigator · Hebei Provincial Eye Hospital
Dan Zhu, Doctor
principal investigator · The Affiliated Hospital of Inner Mongolia Medical University
Xuemei Pan, Master
principal investigator · The Affiliated Eye Hospital of Shandong University of Chinese Medicine
Yanfei Qiu, Doctor
principal investigator · Pingxiang People's Hospital
Zhen Zhang, Doctor
principal investigator · Xuzhou Central Hospital
Jingbo Li, Doctor
principal investigator · Luoyang Third People's Hospital
Xinyan Xu, Master
principal investigator · Weifang Eye Hospital
Lan Li, Master
principal investigator · The First People's Hospital of Kunming
Hongxia Yang, Bachelor
principal investigator · Jinzhong First People's Hospital
Miaoqin Wu, Doctor
principal investigator · Zhejiang Provincial People's Hospital
Zhaozeng Lu, Doctor
principal investigator · Huashan Hospital
Gangfeng Cui, Doctor
principal investigator · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Quanyong Yi, Doctor
principal investigator · Ningbo Eye Hospital
Ruifeng Wang, Doctor
principal investigator · The Second People's Hospital of Zhengzhou

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAT5906

Start the discussion